Brief: Bioinvent And Cantargia Sign Manufacturing Agreement For Monoclonal Antibody CAN10

BioInvent International AB

26/11/2020 07:36

Nov 26 (Reuters) - CANTARGIA AB  CANTA.ST :
    * BIOINVENT AND CANTARGIA SIGN MANUFACTURING AGREEMENT FOR
MONOCLONAL ANTIBODY CAN10
    * MAJORITY OF WORK WILL BE COMPLETED IN 2021 TO START
CLINICAL
TRIALS AS EARLY AS POSSIBLE DURING 2022.

Source text for Eikon:  ID:nWkr3JFCfh 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))